There is a terrific News release about the Dec. 19th French approval on IHUB, Yet it never made the business wire or yahoo news services? It is a shame becasue it is sensational news and deserving to be read by more then 5 people if that many?
Just one more example how ARI's execution need to be finely tuned and it's time they hired PR already to avoid another mstale lime thisd not being picked up when PR creates a buzz and carries momemtum.
here it is:
Apricus Announces National Phase Approval for Erectile Dysfunction Cream - Vitaros(R) in France
Print
Alert
Vitaros(R) Remains on Track for European Launch in 2014
SAN DIEGO, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today announced that France's National Agency for Medicines and Health Products Safety (ANSM) has granted national phase approval to Vitaros®, indicated for the treatment of patients with erectile dysfunction ("ED"). The Company has now received a total of seven national phase approvals for Vitaros®, including France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom (the "UK") following its broad approval by European health authorities in June 2013.
"The approval of the Vitaros® marketing authorization in France marks a significant milestone for Apricus and Laboratories Majorelle, our commercialization partner in France. We will continue to support Majorelle as they prepare for a successful launch of the first topical, on-demand treatment for ED in one of the largest ED markets in Europe," said Richard Pascoe, Chief Executive Officer of Apricus. "Majorelle's depth and experience in the French urology market gives us great confidence that Vitaros® will achieve long term commercial success in France as a treatment of choice for men suffering from ED."
In June 2013, Apricus announced that its marketing application for Vitaros® was approved through the European Decentralized Procedure ("DCP"). Under the DCP, Apricus filed its application for marketing approval designating the Netherlands as the Reference Member State ("RMS") on behalf of nine other European Concerned Member States ("CMS") participating in the procedure. The Company continues to work toward obtaining country-by-country national phase approvals in the remaining CMS territories including Belgium, Spain and Luxembourg. Once the national phase approvals are secured on a country-by-country basis, marketing of Vitaros® can then be initiated in each country by Apricus' commercialization partners.
Vitaros® is expected to become the first new and novel ED product launched in nearly a decade, and with its unique product profile that addresses a large number of patients who cannot or do not respond well to the existing therapies, or who are intolerant to the systemic effects of PDE-5 inhibitors, is well-positioned for commercial success. In Europe alone, the existing ED products generated over $1 billion in sales in 2012. Apricus believes that a significant portion of the market remains untreated or under-treated, which represents a gigantic need for a drug like Vitaros a quick on demand topcial with little if any side effects and is much safer overall than all Viagra class drugs with a alternative to all Viagra class drugs like Vitaros it is expected to be a blockbuster.
Market Data 
Markets 
AI
